OverviewSuggest Edit

Kaken Pharmaceutical is a company focusing on the development and commercialization of pharmaceuticals and medical devices in the orthopedics and dermatology fields. Its products include streptomycin, anti-tuberculosis, anti-osteoarthritis drugs, film-type absorbable adhesion barrier, wound-healing spray, antifungal agents, etc. Additionally, the company is engaged in drug research and discovery in the immune system, nervous system, and infectious diseases areas.
TypePublic
Founded1948
HQBunkyo City, JP
Websitekaken.co.jp

Latest Updates

Employees (est.) (May 2021)1,268
Share Price (Jul 2021)¥4.9 K
Cybersecurity ratingBMore

Key People/Management at Kaken Pharmaceutical

Hiroyuki Horiuchi

Hiroyuki Horiuchi

President and Representative Director

Kaken Pharmaceutical Office Locations

Kaken Pharmaceutical has an office in Bunkyo City
Show all (1)

Kaken Pharmaceutical Financials and Metrics

Kaken Pharmaceutical Revenue

Market capitalization (28-Jul-2021)

184.7b

Closing stock price (28-Jul-2021)

4.9k
Kaken Pharmaceutical's current market capitalization is ¥184.7 b.
Show all financial metrics

Kaken Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Kaken Pharmaceutical Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Kaken Pharmaceutical Online and Social Media Presence

Embed Graph

Kaken Pharmaceutical News and Updates

Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

BOULDER, Colo., June 24, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announc…

Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical

Kaken plans to launch ECCLOCK® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020- - -ECCLOCK® placed on Japan’s National Health Insurance (NHI) drug reimbursement price list

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical

Japan is the first country to approve sofpironium bromide with commercial launch expected later this year

Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide

Presentation based on positive Phase 3 pivotal study results of Sofpironium Bromide in Japanese Patients with Primary Axillary Hyperhidrosis Presentation based on positive Phase 3 pivotal study results of Sofpironium Bromide in Japanese Patients with Primary Axillary Hyperhidrosis

Kaken Pharmaceutical Frequently Asked Questions

  • When was Kaken Pharmaceutical founded?

    Kaken Pharmaceutical was founded in 1948.

  • Who are Kaken Pharmaceutical key executives?

    Kaken Pharmaceutical's key executives are Hiroyuki Horiuchi.

  • How many employees does Kaken Pharmaceutical have?

    Kaken Pharmaceutical has 1,268 employees.

  • Who are Kaken Pharmaceutical competitors?

    Competitors of Kaken Pharmaceutical include Kaleo, Nobelpharma and JETEMA.

  • Where are Kaken Pharmaceutical offices?

    Kaken Pharmaceutical has an office in Bunkyo City.

  • How many offices does Kaken Pharmaceutical have?

    Kaken Pharmaceutical has 1 office.